Charles River acquires analytical CRO

By Melissa Fassbender contact

- Last updated on GMT

The acquisition is the latest in a series. (Image: iStock)
The acquisition is the latest in a series. (Image: iStock)

Related tags: Charles river, Executive officer, Management occupations, Chief executive officer

Charles River Laboratories has acquired Blue Stream Laboratories, expanding the company’s biologic and biosimilar development capabilities.

The Woburn, Massachusetts-based contract research organization (CRO) has expertise in structural and functional protein characterization programs as well as background in the development and validation of assays for current good manufacturing practice (cGMP) lot release and stability programs.

Through the acquisition, Charles River will have the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization.

James C. Foster, Chairman, President and Chief Executive Officer, said that the company is continuing to invest in expanding its biologics portfolio, especially as more biologic and biosimilar drugs are in development.

The investment announced today is the latest in a series of acquisitions, coming months after it finalized its acquisition of the CDMO, WIL Research.

As Outsourcing-Pharma.com previously reported​, Charles River predicted 2016 to be a “robust year,” driven mainly by customer demand and enhanced strategic partnerships. 

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Related suppliers

Follow us

Products

View more

Webinars